Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6589158 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL9348641 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL440314 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7927733 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL1820900 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL23026283 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7919319 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8614599 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL15353147 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8586429 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305284-B1 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | UNIV MICHIGAN STATE (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1305284-A4 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | UNIV MICHIGAN STATE (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1305284-A1 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | MICHIGAN STATE UNIVERSITY (US) | 2003-05-02 | — | — | EP | claimed |
| US-6423867-B1 | FROM TRI-O-ACETYL-D-ERYTHRO-4-PENTULOSONIC ACID ESTERS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2002-07-23 | — | — | US | claimed |
| US-20020026071-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES, OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-28 | — | — | US | claimed |
| US-20020026073-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-28 | — | — | US | claimed |
| US-20020026072-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2002-02-28 | — | — | US | claimed |
| US-20020026074-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERS | 2002-02-28 | — | — | US | claimed |
| US-20020019542-A1 | Process and intermediate compounds for the preparation of pyrrolidines | MICHIGAN STATE UNIVERSITY BOARD OF TRUSTEES OPERATING | 2002-02-14 | — | — | US | claimed |
| US-20020019561-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-14 | — | — | US | claimed |
| WO-2002010130-A1 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | MICHIGAN STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
| US-5659022-A | Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids | EPOCH PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | claimed |
| EP-1305284-B1 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | UNIV MICHIGAN STATE (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1947084-A2 | 2-Pyrrolidones as intermediates for the preparation of pyrrolidines | MICHIGAN STATE UNIVERSITY (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1947082-A2 | Oximes or imines of 4-pentulosonic acid methyl esters as intermediates for the preparation of pyrrolidines | MICHIGAN STATE UNIVERSITY (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1305284-A4 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | UNIV MICHIGAN STATE (US) | 2005-08-03 | — | — | EP | disclosed |
| US-5955597-A | NUCLEOSIDES WHICH HYBRIDIZE TO RNA TARGET SEQUENCES, DIMERS, TRIMERS OR TETRAMERS | GENTA, INCORPORATED (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0731809-A1 | CHIRALLY ENRICHED SYNTHETIC PHOSPHONATE OLIGOMERS | GENTA INCORPORATED (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995014031-A1 | CHIRALLY ENRICHED SYNTHETIC PHOSPHONATE OLIGOMERS | GENTA INCORPORATED (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026073-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
| US-20020026071-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
| US-20020019542-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
| US-20020026074-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
| US-20020026072-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
| US-20020019561-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | LGALS8 2666/4885OGA 182/4885SLC2A1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.